|
Management
Goal and Strategies
The Company’s
goal is to have the Company become an industry-leading biotechnology company using the Cell-in-a-Box® technology
as a platform upon which treatments for cancer and diabetes are developed and obtain marketing approval for these treatments by
regulatory agencies in the United States, the European Union, Australia and Canada.
The Company’s
strategies to achieve this goal consist of the following:
| |
· |
The completion of the preparations for
a Phase 2b clinical trial in advanced, inoperable non-metastatic pancreatic cancer and its associated pain to be conducted
by Translational Drug Development, LLC (“TD2”) in the United States with study sites in Europe and Australia; |
| |
· |
The completion of the preparations for
a clinical trial that will examine the effectiveness of the Company’s pancreatic cancer treatment in reducing the production
and accumulation of malignant ascites fluid in the abdomen that is characteristic of pancreatic and other abdominal cancers.
This clinical trial will be conducted by TD2 in the United States; |
| |
· |
The completion of preclinical studies
that involve the encapsulation of the Melligen cells using the Cell-in-a-Box® technology to develop a treatment
for Type 1 diabetes and Type 2 insulin-dependent diabetes; |
| |
· |
The enhancement of the Company’s
ability to expand into the biotechnology arena through further research and partnering agreements in cancer and diabetes; |
| |
· |
The acquisition of contracts that generate
revenue or provide research and development capital utilizing the Company’s sublicensing rights; |
| |
· |
The further development of uses of the
Cell-in-a-Box® technology platform through contracts, licensing agreements and joint ventures with other companies;
and |
| |
· |
The completion of testing, expansion
and marketing of existing and newly derived product candidates. |
|